ID   143B
AC   CVCL_2270
SY   143b; 143 B; 143B TK-; 143B.TK-; 143BTK-; 143TK-; HOS-143B; HOS-143b; GM05887; GM05887A
DR   BTO; BTO:0003167
DR   CLO; CLO_0001084
DR   CLO; CLO_0001088
DR   CLO; CLO_0024221
DR   EFO; EFO_0006355
DR   CLDB; cl10
DR   CLDB; cl11
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; CRL-8303
DR   BCRC; 60439
DR   BioGRID_ORCS_Cell_line; 315
DR   BioSample; SAMN03471904
DR   cancercelllines; CVCL_2270
DR   CCRID; 1101HUM-PUMC000363
DR   CCRID; 4201HUM-CCTCC00076
DR   CCTCC; GDC0076
DR   Cell_Model_Passport; SIDM00804
DR   ChEMBL-Cells; CHEMBL3307382
DR   ChEMBL-Targets; CHEMBL614508
DR   Coriell; GM05887
DR   Cosmic; 1074398
DR   Cosmic; 1529910
DR   Cosmic; 2009541
DR   DepMap; ACH-001001
DR   ECACC; 91112502
DR   EGA; EGAS00001000610
DR   GEO; GSM320829
DR   GEO; GSM879206
DR   GEO; GSM886836
DR   GEO; GSM887899
DR   GEO; GSM1914980
DR   GEO; GSM1914981
DR   GEO; GSM1914982
DR   GEO; GSM1914983
DR   GEO; GSM1915018
DR   GEO; GSM1915019
DR   GEO; GSM1915020
DR   GEO; GSM1915021
DR   GEO; GSM1915022
DR   GEO; GSM2635309
DR   GEO; GSM2635310
DR   IARC_TP53; 21149
DR   IARC_TP53; 27023
DR   IZSLER; BS TCL 77
DR   LINCS_LDP; LCL-1417
DR   Lonza; 136
DR   PharmacoDB; 143B_3_2019
DR   PRIDE; PXD002425
DR   Progenetix; CVCL_2270
DR   PubChem_Cell_line; CVCL_2270
DR   TOKU-E; 132
DR   Wikidata; Q54581813
RX   CelloPub=CLPUB00447;
RX   PubMed=2233717;
RX   PubMed=19787792;
RX   PubMed=21519327;
RX   PubMed=22460905;
RX   PubMed=23144859;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26320182;
RX   PubMed=26589293;
RX   PubMed=26852163;
RX   PubMed=29334376;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=36480329;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/1/cell-lines-detail-310.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8303.
CC   Population: Caucasian.
CC   Doubling time: ~36 hours (PubMed=21519327).
CC   HLA typing: A*02:11,02:11; B*52:01,52:01; C*12:02,12:02; DQB1*05:02,05:02; DRB1*15:02,16:05 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=4.02%; South Asian=37%; European, North=0%; European, South=58.98% (PubMed=30894373).
CC   Caution: Could be identical to HTK- (Cellosaurus=CVCL_2522).
CC   Misspelling: I43B; Cosmic=1529910.
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): ATCC; BCRC; CCRID; ECACC; IZSLER; PubMed=19787792; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 17
ST   D19S433: 13
ST   D21S11: 31.2,32.2
ST   D2S1338: 24,25
ST   D3S1358: 15
ST   D5S818: 13 (ATCC; BCRC; CCRID; ECACC; IZSLER; PubMed=25877200)
ST   D5S818: 13,14 (PubMed=19787792)
ST   D7S820: 11,12
ST   D8S1179: 11,14
ST   FGA: 24
ST   Penta D: 9,10
ST   Penta E: 7,12
ST   SE33: 21
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 18 (ATCC; BCRC; CCRID; ECACC; IZSLER; PubMed=25877200)
ST   vWA: 18,19 (PubMed=19787792)
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0312 ! HOS
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990;
RA   Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M.,
RA   Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.;
RT   "p53 functions as a cell cycle control protein in osteosarcomas.";
RL   Mol. Cell. Biol. 10:5772-5781(1990).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:E48262-E48262(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26852163; DOI=10.1074/mcp.M115.053181;
RA   Aretz I., Hardt C., Wittig I., Meierhofer D.;
RT   "An impaired respiratory electron chain triggers down-regulation of
RT   the energy metabolism and de-ubiquitination of solute carrier amino
RT   acid transporters.";
RL   Mol. Cell. Proteomics 15:1526-1538(2016).
//
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=36480329; DOI=10.1002/adbi.202200194;
RA   Low K., Hills F., Roberts H.C., Stordal B.;
RT   "Establishment and characterization of single and triple-agent
RT   resistant osteosarcoma cell lines.";
RL   Adv. Biol. (Weinh.) 7:e2200194.1-e2200194.13(2023).
//